Related Experiment Videos
Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic
K M Kälkner1, C Ginman, S Nilsson
1Department of Oncology, University Hospital, Uppsala University, Sweden.
Abstract:
The discovery of neuroendocrine differentiation in hormone-refractory prostatic adenocarcinoma has opened a potentially new therapeutic approach in this group of patients with a poor prognosis and few effective therapy modalities. Based on previous findings of increased uptake of 11C-5-hydroxytryptophan (11C-5-HTP) in neuroendocrine tumours using the PET technique, this tracer was applied in the study of 10 patients with metastatic hormone-refractory prostatic adenocarcinoma. In three patients, the study was repeated after treatment. An increased uptake of 11C-5-HTP was observed in all investigated skeletal lesions, although the magnitude of the uptake was moderate. The difference between the standard uptake values (SUV) in normal bone and metastatic lesions was significant (p < 0.001). A kinetic analysis of the uptake of 11C-5-HTP demonstrates an increase during the first minutes followed by a wash-out and a stabilization of the tissue/blood ratio at about 2. The Patlak plots demonstrated a gradual increase in the transport rate during the first 20 to 30 min, after which a constant level was observed. The SUV varied between patients and between lesions over time and treatment. The uptake of 11C-5-HTP discriminates metastatic lesions from normal bone and may thus aid in the diagnosis and, potentially, in treatment monitoring of metastatic hormone-refractory prostatic adenocarcinoma. Uptake kinetics are characterized by a wash-out and cannot alone be used as proof of neuroendocrine differentiation in hormone-refractory prostatic adenocarcinoma.
Insights
11C-5-hydroxytryptophan (11C-5-HTP) PET imaging shows increased uptake in metastatic hormone-refractory prostate cancer lesions. This tracer may help diagnose and monitor treatment for this aggressive cancer.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Neuroendocrine differentiation in hormone-refractory prostate adenocarcinoma presents a therapeutic challenge due to poor prognosis and limited treatment options.
- Previous studies indicate elevated uptake of 11C-5-hydroxytryptophan (11C-5-HTP) in neuroendocrine tumors using Positron Emission Tomography (PET).
Purpose of the Study:
- To investigate the utility of 11C-5-HTP PET in patients with metastatic hormone-refractory prostate adenocarcinoma.
- To assess the diagnostic potential of 11C-5-HTP uptake for identifying skeletal metastases and monitoring treatment response.
Main Methods:
- 10 patients with metastatic hormone-refractory prostate adenocarcinoma underwent 11C-5-HTP PET imaging.
- Kinetic analysis and Patlak plots were used to evaluate tracer uptake and transport rates.
- Three patients were rescanned after treatment to assess treatment effects.
Main Results:
- Significant increased uptake of 11C-5-HTP was observed in all skeletal metastatic lesions compared to normal bone (p < 0.001).
- Kinetic analysis revealed an initial increase in uptake followed by wash-out and stabilization.
- Standardized Uptake Values (SUV) showed variability between patients, lesions, and over time/treatment.
Conclusions:
- 11C-5-HTP PET can differentiate metastatic lesions from normal bone in hormone-refractory prostate adenocarcinoma.
- This imaging modality shows potential for aiding diagnosis and monitoring treatment response.
- Uptake kinetics, including wash-out, require careful interpretation and cannot solely confirm neuroendocrine differentiation.